MetaVia

Biotechnology ResearchMassachusetts, United States11-50 Employees

MetaVia (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).

DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for once-a-week injection. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

Our strategic partner and the largest investor, Dong-A ST Co. Ltd., is part of the Dong-A Socio Group of companies established in 1932 and based in South Korea. MetaVia has the full support of Dong-A ST’s Research center, providing the company with access to R&D, scientific and CMC expertise.

Sign up for free to view info

Email Format Employee directory